New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
07:08 EDTSPPISpectrum announces 'encouraging' data from MARQIBO, FOLOTYN studies
Spectrum Pharmaceuticals announced encouraging clinical data from investigator-sponsored studies of MARQIBO and FOLOTYN. The company said, "Data from MARQIBO’s Phase 2 study suggests the drug potentially could have utility in the treatment of Diffuse Large B-cell Lymphoma in the front-line setting. These data reinforce our excitement in MARQIBO’s continuing development strategy, which currently includes the ongoing investigator-initiated Phase 3 Optimal>60 trial being conducted by the German High-Grade NHL Study Group in the same patient population. The second abstract provides data on the use of FOLOTYN as front-line therapy in patients with Peripheral T-cell Lymphoma. These findings suggest that FOLOTYN may provide benefit to patients with early stage disease, a setting that we are currently exploring in a large Phase 3 study.”
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:08 EDTSPPISpectrum names Joseph Turgeon COO
Spectrum disclosed in a regulatory filing that effective April 17, Spectrum Pharmaceuticals appointed Joseph Turgeon as its President and COO. Mr. Turgeon will have global responsibility for leading Commercial Operations, Medical and Clinical Development and Pharmaceutical Operations. On April 17, Ken Keller resigned from his position as EVP and COO of the company in order to assume the role of CEO of an organization on the east coast. Mr. Keller will continue to be employed by the company through April 28 in order to assist with the transition. Keller’s resignation was not the result of any disagreement with the company on any matter relating to the company’s operations, policies or practices.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use